Angiotensin II and endothelin-1 augment the vascular complications of diabetes via JAK2 activation

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 293, Issue 2, 2007, Pages

  Banes Berceli, Amy K L ^a   Ketsawatsomkron, Pimonrat ^a   Ogbi, Safia ^a   Patel, Bela ^a   Pollock, David M ^a   Marrero, Mario B ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Angiotensin II; Janus activated kinase 2; Signal transducer and activator of transcription; Type 1 diabetes; Vascular smooth muscle cells

Indexed keywords

ANGIOTENSIN II; ATRASENTAN; CANDESARTAN; ENDOTHELIN 1; JANUS KINASE 2; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; STREPTOZOCIN DIABETES; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA, THORACIC; BENZIMIDAZOLES; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; ENDOTHELIN-1; ENZYME ACTIVATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JANUS KINASE 2; MALE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE-PHOSPHATASE; PYRROLIDINES; RATS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ENDOTHELIN A; SHP1 PROTEIN TYROSINE PHOSPHATASE; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; TETRAZOLES; TIME FACTORS; TYRPHOSTINS; VASODILATION;

EID: 34547909932     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00181.2007     Document Type: Article

References (31)

1. Amiri F, Shaw S, Wang X, Tang J, Waller JL, Eaton DC, Marrero MB. Angiotensin II activation of the JAK/STAT pathway in mesangial cells is altered by high glucose. Kidney Int 61: 1605-1616, 2002.
2. An SJ, Boyd R, Wang Y, Qiu X, Wang HD. Endothelin-1 expression in vascular adventitial fibroblasts. Am J Physiol Heart Circ Physiol 290: H700-H708, 2006.
3. Ayo SH, Radnik R, Garoni JA, Troyer DA, Kreisberg JI. High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell cultures. Am J Physiol Renal Fluid Electrolyte Physiol 261: F571-F577, 1991.
4. Balakrishnan S, Wang H, Gopalakrishnan V, Wilson McNeill JT. Effect of an endothelin antagonist on hemodynamic responses to angiotensin II. Hypertension 28: 806-809, 1996.
5. Banes AK, Shaw S, Jenkins J, Redd H, Amiri F, Pollock DM, Marrero MB. Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli. Am J Physiol Renal Physiol 286: F653-F659, 2004.
6. Banes AK, Shaw SM, Tawfik A, Patel BP, Ogbi S, Fulton D, Marrero MB. Activation of the JAK/STAT pathway in vascular smooth muscle by serotonin. Am J Physiol Cell Physiol 288: C805-C812, 2005.
7. Banes-Berceli AK, Ogobi S, Tawfik A, Patel B, Shirley A, Pollock DM, Fulton D, Marrero MB. Endothelin-1 activation of JAK2 in vascular smooth muscle cells involves NAD(P)H oxidase-derived reactive oxygen species. Vascul Pharmacol 43: 310-319, 2005.
8. Ceriello A, Mercuri F, Quagliaro L, Assaloni R, Motz E, Tonutti L, Taboga C. Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia 44: 834-838, 2001.
9. D'Uscio LV, Moreau P, Shaw A, Takase H, Barton M, Luscher TF. Effect of chronic ETA-receptor blockade in angiotensin II-induced hypertension. Hypertension 29: 435-441, 1997.
10. Glowinska B, Urban M, Hryniewicz A, Peczynska J, Florys B, Al-Hwish M. Endothelin-1 plasma concentration in children and adolescents with atherogenic risk factors. Kardiol Pol 61: 329-338, 2004.
11. Gonzalez-Santiago L, Lopez-Ongil S, Griera M, Rodriguez-Puyol M, Rodriguez-Puyol D. Regulation of endothelin synthesis by extracellular matrix in human endothelial cells. Kidney Int 62: 537-543, 2002.
12. Jones ML, Craik JD, Gibbins JM, Poole AW. Regulation of SHP-1 tyrosine phosphatase in human platelets by serine phosphorylation at its C terminus. J Biol Chem 279: 40475-40483, 2004.
13. Kang N, Alexander G, Park JK, Maasch C, Buchwalow I, Luft FC, Haller H. Differential expression of protein kinase C isoforms in streptozotocin-induced diabetic rats. Kidney Int 56: 1737-1750, 1999.
14. 2 regulates the activation of distinct MAPK pathways. Free Radic Biol Med 33: 1121-1132, 2002.
15. Marshall SM, Flyvbjerg A. Prevention and early detection of vascular complications of diabetes. BMJ 333: 475-480, 2006.
16. Marrero MB, Venema VJ, Ju H, Eaton DC, Venema RC. Regulation of angiotensin II-induced JAK2 tyrosine phosphorylation: roles of SHP-1 and SHP-2. Am J Physiol Cell Physiol 275: C1216-C1223, 1998.
17. A-receptor antagonist. Circulation 96: 1593-1597, 1997.
18. Oparil S, Silfani TN, Walker JF. Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals. Am J Hypertens 18: 287-294, 2005.
19. Pershadsingh HA. Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferatoractivated receptor-γ. Int J Biochem Cell Biol 38: 766-781, 2006.
20. Pollock DM, Rekito A. Hypertensive response to chronic NO synthase inhibition is different in Sprague-Dawley rats from two suppliers. Am J Physiol Regul Integr Comp Physiol 275: R1719-R1723, 1998
21. Poole AW, Jones ML. A SHPing tale: perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the C-terminal tail. Cell Signal 17: 1323-1332, 2005.
22. Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCOMCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 17: 189-212, 2001.
23. Russo D, Minutolo R, Clienti C, De Nicola L, Iodice C, Savino FA, Andreucci VE. Endothelin-1 released by vascular smooth muscle cells enhances vascular responsiveness of rat mesenteric arterial bed exposed to high perfusion flow. Am J Hypertens 12: 1119 -1123, 1999.
24. Sasser JM, Sullivan JC, Hobbs JL, Yamamoto T, Pollock DM, Carmines PK, Pollock JS. Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol 18: 143-154, 2007.
25. Seki Y, Kai H, Shibata R, Nagata T, Yasukawa H, Yoshimura A, Imaizumi T. Role of the JAK/STAT pathway in rat carotid artery remodeling after vascular injury. Circ Res 87: 12-18, 2000.
26. Shaw S, Wang X, Redd H, Alexander GD, Isales CM, Marrero MB. High glucose augments the angiotensin II-induced activation of JAK2 in vascular smooth muscle cells via the polyol pathway. J Biol Chem 278: 30634-30641, 2003.
27. Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. Hypertension 26: 869-879, 1995.
28. Tang EY, Parker PJ, Beattie J, Houslay MD. Diabetes induces selective alterations in the expression of protein kinase C isoforms in hepatocytes. FEBS Lett 326: 117-123, 1993.
29. Tawfik A, Jin L, Banes-Berceli AK, Caldwell RB, Ogbi S, Shirley A, Barber D, Catravas JD, Stern DM, Fulton D, Caldwell RW, Marrero MB. Hyperglycemia and reactive oxygen species mediate apoptosis in aortic endothelial cells through Janus kinase 2. Vascul Pharmacol 43: 320-326, 2005.
30. Yamagishi S, Takeuchi M. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-γ-inducing property. Med Hypotheses 64: 476-478, 2005.
31. Zor T, Selinger Z. Linearization of the Bradford protein assay increases its sensitivity: theoretical and experimental studies. Anal Biochem 236: 302-308, 1996.